Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.50
AMAG's Cash-to-Debt is ranked lower than
89% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. AMAG: 0.50 )
Ranked among companies with meaningful Cash-to-Debt only.
AMAG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: No Debt Max: No Debt
Current: 0.5
0.29
No Debt
Equity-to-Asset 0.40
AMAG's Equity-to-Asset is ranked lower than
75% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AMAG: 0.40 )
Ranked among companies with meaningful Equity-to-Asset only.
AMAG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.82 Max: 0.99
Current: 0.4
0.33
0.99
Debt-to-Equity 1.00
AMAG's Debt-to-Equity is ranked lower than
81% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. AMAG: 1.00 )
Ranked among companies with meaningful Debt-to-Equity only.
AMAG' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.73  Med: 1 Max: 1.17
Current: 1
0.73
1.17
Debt-to-EBITDA -6.16
AMAG's Debt-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. AMAG: -6.16 )
Ranked among companies with meaningful Debt-to-EBITDA only.
AMAG' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.16  Med: 6.07 Max: 114.16
Current: -6.16
-6.16
114.16
Interest Coverage 0.32
AMAG's Interest Coverage is ranked lower than
99.99% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMAG: 0.32 )
Ranked among companies with meaningful Interest Coverage only.
AMAG' s Interest Coverage Range Over the Past 10 Years
Min: 0.32  Med: No Debt Max: No Debt
Current: 0.32
0.32
No Debt
Piotroski F-Score: 5
Altman Z-Score: -0.09
Beneish M-Score: -2.40
WACC vs ROIC
2.39%
1.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 3.42
AMAG's Operating Margin % is ranked higher than
57% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. AMAG: 3.42 )
Ranked among companies with meaningful Operating Margin % only.
AMAG' s Operating Margin % Range Over the Past 10 Years
Min: -4107.64  Med: -15.61 Max: 30.26
Current: 3.42
-4107.64
30.26
Net Margin % -35.17
AMAG's Net Margin % is ranked higher than
60% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. AMAG: -35.17 )
Ranked among companies with meaningful Net Margin % only.
AMAG' s Net Margin % Range Over the Past 10 Years
Min: -3696.96  Med: -26.14 Max: 109.19
Current: -35.17
-3696.96
109.19
ROE % -25.81
AMAG's ROE % is ranked higher than
61% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. AMAG: -25.81 )
Ranked among companies with meaningful ROE % only.
AMAG' s ROE % Range Over the Past 10 Years
Min: -52.39  Med: -16.29 Max: 42.96
Current: -25.81
-52.39
42.96
ROA % -10.42
AMAG's ROA % is ranked higher than
69% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. AMAG: -10.42 )
Ranked among companies with meaningful ROA % only.
AMAG' s ROA % Range Over the Past 10 Years
Min: -44.82  Med: -7.79 Max: 16.42
Current: -10.42
-44.82
16.42
ROC (Joel Greenblatt) % -1260.83
AMAG's ROC (Joel Greenblatt) % is ranked lower than
64% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. AMAG: -1260.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMAG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1260.83  Med: -488.06 Max: 481.05
Current: -1260.83
-1260.83
481.05
3-Year Revenue Growth Rate 52.50
AMAG's 3-Year Revenue Growth Rate is ranked higher than
87% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. AMAG: 52.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AMAG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -78.7  Med: 10.3 Max: 278.5
Current: 52.5
-78.7
278.5
GuruFocus has detected 4 Warning Signs with AMAG Pharmaceuticals Inc AMAG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMAG's 30-Y Financials

Financials (Next Earnings Date: 2018-08-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

AMAG Guru Trades in Q2 2017

Joel Greenblatt 800,055 sh (+17.84%)
Jim Simons 778,800 sh (+1.67%)
Paul Tudor Jones Sold Out
» More
Q3 2017

AMAG Guru Trades in Q3 2017

Chuck Royce 575 sh (New)
Jim Simons 681,000 sh (-12.56%)
Joel Greenblatt 431,411 sh (-46.08%)
» More
Q4 2017

AMAG Guru Trades in Q4 2017

Pioneer Investments 67,100 sh (New)
Chuck Royce 859 sh (+49.39%)
Jim Simons 851,900 sh (+25.10%)
Joel Greenblatt 73,141 sh (-83.05%)
» More
Q1 2018

AMAG Guru Trades in Q1 2018

Paul Tudor Jones 12,344 sh (New)
Charles Brandes 50,424 sh (New)
Jim Simons 1,544,800 sh (+81.34%)
Pioneer Investments Sold Out
Joel Greenblatt Sold Out
Chuck Royce 613 sh (-28.64%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:AMAG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2018-03-31 New Buy0.02%$12.3 - $21.15 $ 21.8529%50,424
Joel Greenblatt 2018-03-31 Sold Out 0.01%$12.3 - $21.15 $ 21.8529%0
Joel Greenblatt 2017-12-31 Reduce -83.05%0.1%$12.8 - $19.45 $ 21.8545%73,141
Joel Greenblatt 2017-09-30 Reduce -46.08%0.1%$16.55 - $20.45 $ 21.8517%431,411
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:OMER, SZSE:300583, NAS:CBAY, XKRX:084110, NAS:BYSI, HKSE:00775, NAS:DCPH, NAS:GLYC, XKRX:199800, SZSE:300381, NAS:NCNA, ROCO:4162, NAS:RETA, NAS:ANIP, TSE:3034, NAS:CHRS, NAS:CERS, NAS:RCKT, OSTO:PROB, TSE:4593 » details
Traded in other countries:AMU.Germany,
Headquarter Location:USA
AMAG Pharmaceuticals Inc is a biopharmaceutical company, which utilizes the technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and to aid in the diagnosis of cancer.

Founded in 1981, AMAG Pharmaceuticals uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging.

Top Ranked Articles about AMAG Pharmaceuticals Inc

Analysis: Positioning to Benefit within The Stars Group, AMAG Pharmaceuticals, ResMed, WestRock, Briggs & Stratton, and II-VI — Research Highlights Growth, Revenue, and Consolidated Results
California Cryobank And Cord Blood Registry To Be Combined By GI Partners To Create A Leading Life Sciences Platform
AMAG Pharmaceuticals Announces Divestiture of Cord Blood Registry®
AMAG Pharmaceuticals, Inc. and March of Dimes Announce Collaboration to Improve Health of Mothers and Babies
Brandes Investment's Top 7 Positions in the 1st Quarter Pharmaceuticals, which have reported gains so far, keep the value investment firm busy even after the retirement of its founder
Brandes Investment, the firm established by Charles Brandes (Trades, Portfolio), established seven new positions in the first quarter. Read more...
AMAG Pharmaceuticals Announces FDA Acceptance of New Drug Application Filing for Bremelanotide
AMAG Pharmaceuticals to Present at Upcoming Investor Conference
AMAG Pharmaceuticals Commends CMS for Clarifying Part D Coverage of Treatments for Moderate to Severe Dyspareunia Due to Menopause
AMAG Pharmaceuticals Appoints J. Alan Butcher as Executive Vice President and Chief Business Officer
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

Ratios

vs
industry
vs
history
Forward PE Ratio 9.54
AMAG's Forward PE Ratio is ranked higher than
89% of the 71 Companies
in the Global Biotechnology industry.

( Industry Median: 24.45 vs. AMAG: 9.54 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 0.99
AMAG's PB Ratio is ranked higher than
94% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. AMAG: 0.99 )
Ranked among companies with meaningful PB Ratio only.
AMAG' s PB Ratio Range Over the Past 10 Years
Min: 0.56  Med: 2.12 Max: 6.02
Current: 0.99
0.56
6.02
PS Ratio 1.19
AMAG's PS Ratio is ranked higher than
93% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMAG: 1.19 )
Ranked among companies with meaningful PS Ratio only.
AMAG' s PS Ratio Range Over the Past 10 Years
Min: 0.74  Med: 5.57 Max: 505.93
Current: 1.19
0.74
505.93
Price-to-Free-Cash-Flow 4.76
AMAG's Price-to-Free-Cash-Flow is ranked higher than
90% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 33.20 vs. AMAG: 4.76 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AMAG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.24  Med: 9 Max: 1492.35
Current: 4.76
3.24
1492.35
Price-to-Operating-Cash-Flow 4.53
AMAG's Price-to-Operating-Cash-Flow is ranked higher than
91% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 30.32 vs. AMAG: 4.53 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AMAG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.15  Med: 8.81 Max: 1409.44
Current: 4.53
3.15
1409.44
EV-to-EBIT -3.69
AMAG's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. AMAG: -3.69 )
Ranked among companies with meaningful EV-to-EBIT only.
AMAG' s EV-to-EBIT Range Over the Past 10 Years
Min: -787.3  Med: -3.8 Max: 100.3
Current: -3.69
-787.3
100.3
EV-to-EBITDA -9.29
AMAG's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. AMAG: -9.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMAG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -180.4  Med: -5.2 Max: 479.9
Current: -9.29
-180.4
479.9
EV-to-Revenue 1.77
AMAG's EV-to-Revenue is ranked higher than
92% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. AMAG: 1.77 )
Ranked among companies with meaningful EV-to-Revenue only.
AMAG' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.3  Med: 3.1 Max: 435.3
Current: 1.77
0.3
435.3
Current Ratio 1.57
AMAG's Current Ratio is ranked lower than
77% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. AMAG: 1.57 )
Ranked among companies with meaningful Current Ratio only.
AMAG' s Current Ratio Range Over the Past 10 Years
Min: 1.51  Med: 9.33 Max: 62.43
Current: 1.57
1.51
62.43
Quick Ratio 1.48
AMAG's Quick Ratio is ranked lower than
75% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. AMAG: 1.48 )
Ranked among companies with meaningful Quick Ratio only.
AMAG' s Quick Ratio Range Over the Past 10 Years
Min: 1.4  Med: 8.98 Max: 61
Current: 1.48
1.4
61
Days Inventory 59.70
AMAG's Days Inventory is ranked higher than
69% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. AMAG: 59.70 )
Ranked among companies with meaningful Days Inventory only.
AMAG' s Days Inventory Range Over the Past 10 Years
Min: 59.7  Med: 403.83 Max: 1713.48
Current: 59.7
59.7
1713.48
Days Sales Outstanding 59.14
AMAG's Days Sales Outstanding is ranked higher than
53% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. AMAG: 59.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMAG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.4  Med: 62.66 Max: 581.14
Current: 59.14
27.4
581.14
Days Payable 28.82
AMAG's Days Payable is ranked lower than
77% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. AMAG: 28.82 )
Ranked among companies with meaningful Days Payable only.
AMAG' s Days Payable Range Over the Past 10 Years
Min: 11.5  Med: 109.79 Max: 2881.25
Current: 28.82
11.5
2881.25

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.00
AMAG's 3-Year Average Share Buyback Ratio is ranked higher than
56% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. AMAG: -10.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMAG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -28.7  Med: -7.4 Max: 0.7
Current: -10
-28.7
0.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.41
AMAG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
97% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 3.54 vs. AMAG: 0.41 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AMAG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.27  Med: 4.69 Max: 96.83
Current: 0.41
0.27
96.83
Price-to-Median-PS-Value 0.22
AMAG's Price-to-Median-PS-Value is ranked higher than
94% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. AMAG: 0.22 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMAG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 1.78 Max: 237.57
Current: 0.22
0.14
237.57
Earnings Yield (Greenblatt) % -27.48
AMAG's Earnings Yield (Greenblatt) % is ranked lower than
78% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. AMAG: -27.48 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMAG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -458.4  Med: -12.5 Max: 7.1
Current: -27.48
-458.4
7.1

More Statistics

Revenue (TTM) (Mil) $616.83
EPS (TTM) $ -6.21
Beta0.18
Volatility63.97%
52-Week Range $11.93 - 25.63
Shares Outstanding (Mil)34.33

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 540 533 595
EBIT (Mil $)
EBITDA (Mil $) 129 124 174
EPS ($) -4.00 0.17 1.79
EPS without NRI ($) -4.00 0.17 1.79
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}